Detrusor Overactivity May Be a Prognostic Factor for Better Response to Combination Therapy Over Monotherapy in Male Patients With Benign Prostatic Enlargement and Storage Lower Urinary Tract Symptoms
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Several trials have shown that in men with overactive bladder (OAB) and benign prostate enlargement (BPE), the combination of an α-blocker with an anticholinergic is superior to α-blocker monotherapy. The purpose of this study is to explore whether urodynamic detrusor overactivity (DO) affects clinical outcomes in men with BPE and OAB. Methods: This is a post hoc analysis of a prospective, randomized trial, designed to evaluate the changes of morphometric parameters of the prostate following monotherapy or combination therapy in men with BPE-OAB. The initial study recruited men aged ≥50 years, with BPE and predominantly storage lower urinary tract symptoms (LUTS). Patients were randomized to receive tamsulosin monotherapy or a combination of tamsulosin and solifenacin for 26 weeks. All participants completed a 3-day bladder diary and the International Prostate Symptom Score (IPSS), and then underwent pressure-flow and ultrasonographic studies. Data were stratified and analysed based on the urodynamic observation of DO at baseline (DO vs. non-DO). The primary endpoint was the mean change in urgency episodes from baseline. Secondary outcomes were the changes in nocturia, total IPSS, and urodynamic parameters. Results: Sixty-nine men were initially randomized, but only 60 men were included in this analysis. Urgency episodes significantly improved in men with DO who received combination therapy compared to the DO monotherapy subgroup (P=0.04) or to the non-DO combination treatment subgroup (P=0.038). Nocturia also improved in the DO combination treatment subgroup as compared to the non-DO combination subgroup (P=0.037). The 24-hour frequency and total IPSS significantly improved from baseline without significant differences among the subgroups. Conclusions: The present study suggests that baseline DO could be a prognostic factor for a better response to combination therapy over monotherapy in men with BPE and storage LUTS.
Abstract
Purpose: Several trials have shown that in men with overactive bladder (OAB) and benign prostate enlargement (BPE), the combination of an α-blocker with an anticholinergic is superior to α-blocker monotherapy. The purpose of this study is to explore whether urodynamic detrusor overactivity (DO) affects clinical outcomes in men with BPE and OAB. Methods: This is a post hoc analysis of a prospective, randomized trial, designed to evaluate the changes of morphometric parameters of the prostate following monotherapy or combination therapy in men with BPE-OAB. The initial study recruited men aged ≥50 years, with BPE and predominantly storage lower urinary tract symptoms (LUTS). Patients were randomized to receive tamsulosin monotherapy or a combination of tamsulosin and solifenacin for 26 weeks. All participants completed a 3-day bladder diary and the International Prostate Symptom Score (IPSS), and then underwent pressure-flow and ultrasonographic studies. Data were stratified and analysed based on the urodynamic observation of DO at baseline (DO vs. non-DO). The primary endpoint was the mean change in urgency episodes from baseline. Secondary outcomes were the changes in nocturia, total IPSS, and urodynamic parameters. Results: Sixty-nine men were initially randomized, but only 60 men were included in this analysis. Urgency episodes significantly improved in men with DO who received combination therapy compared to the DO monotherapy subgroup (P=0.04) or to the non-DO combination treatment subgroup (P=0.038). Nocturia also improved in the DO combination treatment subgroup as compared to the non-DO combination subgroup (P=0.037). The 24-hour frequency and total IPSS significantly improved from baseline without significant differences among the subgroups. Conclusions: The present study suggests that baseline DO could be a prognostic factor for a better response to combination therapy over monotherapy in men with BPE and storage LUTS.
참고문헌 (35)
- Elbadawi A, "Morphometry of the obstructed detrusor. I. Review of the issues", Neurourol Urodyn, 8, pp.163~171 (1989)
- Steers WD, "Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy", J Urol, 155, pp.379~385 (1996)
- Irwin DE, "Population based survey of urinary incontinence, overactive bladde, and other lower urinary tract symptoms in five countries:results of the EPIC study", Eur Urol, 50, pp.1306~1315 (2006)
- Haylen BT, "Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity", Int Urogynecol J Pelvic floor Dysfunct, 18, pp.123~128 (2007)
- Apostolidis A, "Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters and quality of life of patients with urodynamic increased bladder sensation", Eur Urol, 50, pp.1299~1305 (2006)
- Blake-James BT, "The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a systematic review and metaanalysis", BJU Int, 99, pp.85~96 (2007)
- Athanasopoulos A, "Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study", J Urol, 169, pp.2253~2256 (2003)
- Kaplan SA, "Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia", J Urol, 174, pp.2273~2275 (2005)[DOI]
- Lee JY, "Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder", BJU Int, 94, pp.817~820 (2004)
- van Kerrebroeck P, "Combination therapy with solifenacin and tamsulosin oral controlled absorption system in asingle tablet for lower urinary tract symptoms in men : efficacy and safety results from the randomized controlled NEPTUNE trial", Eur Urol, 64, pp.1003~1012 (2013)
- Kaplan S, "Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia", Urology, 68, pp.328~332 (2006)
- Roehrborn CG, "Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms : effects of prostate size", Eur Urol, 55, pp.472~481 (2009)
- Chapple CR, "Efficacy and safety of tolterodine extended release in men with overactive bladder symptoms treated with an a-blocker α-blocker : effect of baseline prostate-specific antigen concentration", BJU Int, 106, pp.1332~1338 (2010)
- Sakalis V, "Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms : results from a randomized pilot study", Int J Urol, 25, pp.737~745 (2018)
- Abrams P, "The standardization of terminology in lower urinary tract function : report from the standardization subcommittee of the International Continence Society", Urology, 61, pp.37~49 (2003)
- Andersson KE, "Antimuscarinic mechanisms and overactive detrusor : an update", Eur Urol, 59, pp.377~386 (2011)
- Finney SM, "Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome : motor or sensory actions", BJU Int, 98, pp.503~507 (2006)
- Stohrer M, "Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial", Urol int, 47, pp.138~143 (1991)
- Van Kerrebroeck P, "Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: Results from a phase 2, dose-finding study (Saturn)", Eur Urol, 64, pp.398~407 (2013)
- Abrams P, "Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomized, double-blind, dose-rabging, phase 2 study (Symphony)", Eur Urol, 67, pp.577~588 (2015)
- Mallone-Lee JG, "Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinc treatment response", BJU Int, 92, pp.415~417 (2003)
- Digesu GA, "Overactive bladder symptoms : do we need urodynamics", Neurourol Urodyn, 22, pp.105~108 (2003)
- Michelotti GA, "α1-Adrenergic receptor regulation : basic science and clinical implications", Pharmacol Therapeut, 88, pp.281~309 (2000)
- De Nunzio C, "The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction", J Urol, 169, pp.535~539 (2003)
- 김성은, "Effects of Tamsulosin on Urinary Bladder Function and Neuronal Activity in the Voiding Centers of Rats with Cyclophosphamide-induced Overactive Bladder", International Neurourology Journal, 16(1), pp.13~22 (2012), 대한배뇨장애요실금학회
- Yokoyama O, "Improvements in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rates", J Urol, 177, pp.771~775 (2007)
- Barendrecht MM, "The effect of bladder outlet obstruction on α1-an β-Adrenoceptor expression and function", Neurourol Urodyn, 28, pp.349~355 (2009)
- Michel MC, "Urinary tract" (2011), Springer
- Monica FZ, "Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces beta(3)-adrenoceptor-mediated relaxation, causing rat detrusor overactivity", Br J Pharmacol, 153, pp.1659~1668 (2008)
- Hampel C, "Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction", J Urol, 167, pp.1513~1521 (2002)
- Homma Y, "Epidemiologic survey of lower urinary tract symptoms in Japan", Urology, 68, pp.560~564 (2006)
- Espuna-Pons M, "Nocturia in patients with overactive bladder", Arch Esp Urol, 63, pp.363~372 (2010)
- Oelke M, "Nocturia improvement in the combination of avodart and tamsulosin", World J Urol, 32, pp.1133~1140 (2014)
- Sakalis VI, "Medical treatment of nocturia in men with lower urinary tract symptoms : systematic review by the European Association of Urology Guidelines Panel for male lower urinary tract symptoms", Eur Urol, 72, pp.757~769 (2017)
- Clemens JQ, "Prevalence, subtypes and correlates of nocturia in the symptoms of lower Urinary Tract Dysfunction Research Network cohort", Neurourol Urodyn, 39, pp.1098~1107 (2020)